Gabay Avraham 4

What Happened

• Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals, was granted 95,889 Restricted Stock Units (RSUs) on March 17, 2026. The award was reported at $0.00 per unit (a non‑cash grant). Each RSU represents the right to receive one share of Oramed common stock upon vesting.

Key Details

• Transaction type: Award/Grant (code A)
• Transaction date: 2026-03-17; Filing date: 2026-03-18 (filed promptly)
• Grant size: 95,889 RSUs; reported acquisition price: $0.00
• Vesting: RSUs vest ratably in 8 quarterly installments beginning April 1, 2026 (per footnote)
• Shares owned after transaction: not disclosed in the provided filing
• Footnote: Each RSU equals one share of common stock (par value $0.012); this is a standard equity compensation grant

Context

• RSUs are a form of compensation that convert into shares as they vest; this grant is not a market purchase or sale and does not by itself indicate immediate bullish or bearish trading by the insider. Vesting over eight quarters spreads the eventual share issuance over about two years.